Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma.

Piña Y, Fusco MJ, Macaulay RJ, Walko CM, Peguero E, Evernden BR, Smalley KS, Forsyth P.

J Neurol. 2019 Nov 21. doi: 10.1007/s00415-019-09575-8. [Epub ahead of print]

PMID:
31748891
2.

Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.

Thompson EM, Landi D, Ashley D, Keir ST, Bigner D.

J Neurooncol. 2018 Nov;140(2):261-268. doi: 10.1007/s11060-018-2975-5. Epub 2018 Aug 17.

PMID:
30120661
3.

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.

Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL, Iafrate AJ, Ligon AH, Louis DN, Santagata S.

PLoS One. 2011 Mar 29;6(3):e17948. doi: 10.1371/journal.pone.0017948.

4.

Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.

Vaubel RA, Caron AA, Yamada S, Decker PA, Eckel Passow JE, Rodriguez FJ, Nageswara Rao AA, Lachance D, Parney I, Jenkins R, Giannini C.

Brain Pathol. 2018 Mar;28(2):172-182. doi: 10.1111/bpa.12495. Epub 2017 Apr 2.

5.

Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases.

Smith-Cohn M, Davidson C, Colman H, Cohen AL.

CNS Oncol. 2019 Dec 1;8(4):CNS48. doi: 10.2217/cns-2019-0018. Epub 2019 Dec 10.

6.

Malignant transformation of pleomorphic xanthoastrocytoma and differential diagnosis: case report.

Watanabe N, Ishikawa E, Kohzuki H, Sakamoto N, Zaboronok A, Matsuda M, Shibuya M, Matsumura A.

BMC Neurol. 2020 Jan 15;20(1):21. doi: 10.1186/s12883-020-1601-2.

7.

Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity.

Bernstein A, Mrowczynski OD, Greene A, Ryan S, Chung C, Zacharia BE, Glantz M.

J Neurosurg. 2019 Nov 1:1-6. doi: 10.3171/2019.8.JNS19643. [Epub ahead of print]

PMID:
31675726
8.

Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.

Furuta T, Miyoshi H, Komaki S, Arakawa F, Morioka M, Ohshima K, Nakada M, Sugita Y.

Neuropathology. 2018 Jun;38(3):218-227. doi: 10.1111/neup.12459. Epub 2018 Mar 13.

PMID:
29532523
9.

BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study.

Ma C, Feng R, Chen H, Hameed NUF, Aibaidula A, Song Y, Wu J.

World Neurosurg. 2018 Dec;120:e1225-e1233. doi: 10.1016/j.wneu.2018.09.050. Epub 2018 Sep 18.

PMID:
30240866
10.

Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.

Yamada S, Kipp BR, Voss JS, Giannini C, Raghunathan A.

Am J Surg Pathol. 2016 Feb;40(2):279-84. doi: 10.1097/PAS.0000000000000515.

PMID:
26414224
11.

Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report.

Cicuendez M, Martinez-Saez E, Martinez-Ricarte F, Asanza EC, Sahuquillo J.

J Neurosurg Pediatr. 2016 Jul;18(1):53-7. doi: 10.3171/2016.1.PEDS15558. Epub 2016 Mar 25.

PMID:
27015517
12.

Response to BRAF/MEK Inhibition After Progression With BRAF Inhibition in a Patient With Anaplastic Pleomorphic Xanthoastrocytoma.

Hussain F, Horbinski CM, Chmura SJ, Yamini B, Lukas RV.

Neurologist. 2018 Sep;23(5):163-166. doi: 10.1097/NRL.0000000000000194.

PMID:
30169370
13.

Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.

Chamberlain MC.

J Neurooncol. 2013 Sep;114(2):237-40. doi: 10.1007/s11060-013-1176-5. Epub 2013 Jun 12.

PMID:
23756728
14.

Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation.

Tanaka S, Nakada M, Nobusawa S, Suzuki SO, Sabit H, Miyashita K, Hayashi Y.

Brain Tumor Pathol. 2014 Jul;31(3):172-6. doi: 10.1007/s10014-014-0192-2. Epub 2014 Jun 4.

PMID:
24894018
15.

Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.

Schreck KC, Guajardo A, Lin DDM, Eberhart CG, Grossman SA.

J Natl Compr Canc Netw. 2018 Apr;16(4):343-347. doi: 10.6004/jnccn.2017.7052.

PMID:
29632053
16.

BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.

Suzuki Y, Takahashi-Fujigasaki J, Akasaki Y, Matsushima S, Mori R, Karagiozov K, Joki T, Ikeuchi S, Ikegami M, Manome Y, Murayama Y.

Brain Tumor Pathol. 2016 Jan;33(1):40-9. doi: 10.1007/s10014-015-0234-4. Epub 2015 Oct 7. Review.

PMID:
26445861
17.

Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.

Brown NF, Carter T, Mulholland P.

CNS Oncol. 2017 Jan;6(1):5-9. doi: 10.2217/cns-2016-0031. Epub 2016 Oct 26.

18.

BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.

Tabouret E, Bequet C, Denicolaï E, Barrié M, Nanni I, Metellus P, Dufour H, Chinot O, Figarella-Branger D.

Eur J Surg Oncol. 2015 Dec;41(12):1685-90. doi: 10.1016/j.ejso.2015.09.012. Epub 2015 Sep 30.

PMID:
26454767
19.

MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.

Lohkamp LN, Schinz M, Gehlhaar C, Guse K, Thomale UW, Vajkoczy P, Heppner FL, Koch A.

PLoS One. 2016 Jun 2;11(6):e0156422. doi: 10.1371/journal.pone.0156422. eCollection 2016.

20.

Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.

Ida CM, Rodriguez FJ, Burger PC, Caron AA, Jenkins SM, Spears GM, Aranguren DL, Lachance DH, Giannini C.

Brain Pathol. 2015 Sep;25(5):575-86. doi: 10.1111/bpa.12217. Epub 2014 Dec 5.

Supplemental Content

Support Center